AstraZeneca's Oral GLP-1 Drug Elecoglipron Drives Up To 11.8% Weight Loss In Trial
Published on: June 13, 2026, 7:12 p.m. | Source: NDTV.com
The positive results come from the Phase 2 VISTA clinical trial, which evaluated elecoglipron in adults with obesity or overweight who also had at least one weight-related health condition.
